Lipitor vs Repatha: Head-to-Head Efficacy Compared

How These Two Drugs Lower LDL-C

Atorvastatin blocks HMG-CoA reductase in the liver, reducing cholesterol synthesis and upregulating LDL receptors on hepatocyte surfaces. This dual action pulls LDL particles out of circulation. At 80 mg daily, atorvastatin achieves a mean LDL-C reduction of approximately 50% from baseline, according to the original dose-response data published in the prescribing label and confirmed in multiple trials 1.

Evolocumab works downstream of statins. It binds and neutralizes PCSK9, a protein that tags LDL receptors for degradation. By blocking PCSK9, evolocumab allows more LDL receptors to recycle to the hepatocyte surface, clearing additional LDL particles. In OSLER-1 (N=1,324), evolocumab reduced LDL-C by 61% from baseline at 12 weeks when added to standard therapy 2. The two mechanisms are complementary. Statins upregulate PCSK9 as a compensatory response, which is precisely the target evolocumab eliminates 3. This explains why the combination produces LDL-C levels below 30 mg/dL in some patients, a range that statins alone cannot reach.

Atorvastatin Efficacy: The ASCOT-LLA Evidence

The Anglo-Scandinavian Cardiac Outcomes Trial, Lipid-Lowering Arm (ASCOT-LLA) randomized 10,305 hypertensive patients with total cholesterol of 6.5 mmol/L or less to atorvastatin 10 mg or placebo. The trial was stopped early at a median follow-up of 3.3 years because of a clear benefit signal 4.

Atorvastatin produced a 36% relative risk reduction in primary coronary heart disease events (HR 0.64 to 95% CI 0.50 to 0.83, P = 0.0005). Fatal and non-fatal stroke fell by 27% (HR 0.73, P = 0.024) 4. Total cardiovascular events dropped by 21%. These results emerged in a population that would not have qualified for statin therapy under the guidelines of that era, expanding the indication for primary prevention.

Beyond ASCOT-LLA, the TNT trial (N=10,001) demonstrated that atorvastatin 80 mg reduced major cardiovascular events by 22% compared to atorvastatin 10 mg in patients with stable coronary disease, confirming a dose-response relationship for cardiovascular protection 5. The CARDS trial (N=2,838) in patients with type 2 diabetes showed a 37% reduction in major cardiovascular events with atorvastatin 10 mg versus placebo 6. Across all these trials, atorvastatin's benefit correlates tightly with the magnitude of LDL-C reduction.

Evolocumab Efficacy: The FOURIER Evidence

FOURIER enrolled 27,564 patients with established atherosclerotic cardiovascular disease already receiving statin therapy. Participants were randomized to evolocumab (140 mg every 2 weeks or 420 mg monthly) or placebo. Median follow-up was 2.2 years 7.

Evolocumab reduced LDL-C by 59% from a median baseline of 92 mg/dL to 30 mg/dL. The primary composite endpoint of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization fell by 15% (HR 0.85 to 95% CI 0.79 to 0.92, P < 0.001). The key secondary endpoint of cardiovascular death, MI, or stroke decreased by 20% (HR 0.80, P < 0.001) 7.

A prespecified analysis of FOURIER showed that the benefit of evolocumab grew over time. During the first year, MACE reduction was 12%; from year one onward, it reached 19% 8. This time-dependent pattern suggests that longer treatment durations could yield even greater risk reduction. A FOURIER subgroup analysis also found that patients with baseline LDL-C above 100 mg/dL achieved a 31% relative risk reduction in MI, compared to 14% in the overall population 7.

Why No Direct Head-to-Head Trial Exists

No large randomized trial has compared atorvastatin monotherapy against evolocumab monotherapy. The reason is straightforward: current guidelines from the AHA/ACC and ESC/EAS position statins as foundational therapy, making a statin-free comparator arm ethically difficult to justify in high-risk patients 9.

FOURIER enrolled patients already on statins. ASCOT-LLA compared atorvastatin to placebo. The two trials answer different clinical questions in different populations. ASCOT-LLA asked whether a statin reduces events in moderate-risk hypertensive patients; FOURIER asked whether adding a PCSK9 inhibitor to background statin further reduces events in established ASCVD.

The GAUSS-3 trial (N=511) did compare evolocumab to ezetimibe in statin-intolerant patients, finding that evolocumab lowered LDL-C by 52.8% versus 16.7% for ezetimibe 10. This trial provides the closest look at PCSK9 inhibitor monotherapy efficacy but used ezetimibe as the comparator, not atorvastatin. The 2022 ACC Expert Consensus Decision Pathway explicitly states that PCSK9 inhibitors should be considered after maximally tolerated statin and ezetimibe 11.

Cross-Trial Efficacy Comparison: A Framework

Comparing ASCOT-LLA and FOURIER directly is methodologically imperfect because of differences in baseline risk, concomitant therapies, follow-up duration, and endpoint definitions. Indirect evidence supports a layered interpretation.

Atorvastatin in ASCOT-LLA produced a 36% reduction in coronary events with a baseline LDL-C of approximately 131 mg/dL and a 1.1 mmol/L (42 mg/dL) absolute LDL-C reduction 4. Evolocumab in FOURIER produced a 15% MACE reduction with a baseline LDL-C of 92 mg/dL and a 56 mg/dL absolute LDL-C reduction 7. The smaller relative risk reduction in FOURIER despite a larger absolute LDL-C drop reflects the law of diminishing returns: the lower the starting LDL-C, the smaller the incremental benefit per unit of LDL-C lowered.

The CTT (Cholesterol Treatment Trialists) Collaboration meta-analysis of 26 statin trials (N=170,000) established that each 1 mmol/L (38.7 mg/dL) reduction in LDL-C yields a 22% proportional reduction in major vascular events 12. Using this benchmark, the per-unit efficacy of both drugs aligns with the same underlying biology: lower LDL-C means fewer events, regardless of the pharmacologic mechanism.

The 2019 ESC/EAS guidelines adopted this "lower is better" framework, recommending LDL-C goals below 55 mg/dL for very-high-risk patients and below 40 mg/dL for those with recurrent events within 2 years 13. Reaching these targets almost always requires combination therapy.

LDL-C Reduction: Magnitude and Speed

Atorvastatin achieves near-maximal LDL-C reduction within 2 to 4 weeks of starting therapy. At 10 mg, the reduction averages 39%; at 40 mg, approximately 47%; at 80 mg, roughly 50 to 55% 1. Each doubling of the dose adds about 6% more LDL-C lowering, a pattern known as the "rule of six" for statins.

Evolocumab works faster on a per-dose basis. A single 140 mg injection reduces LDL-C by approximately 60% within 2 weeks 2. In FOURIER, patients reached a median LDL-C of 30 mg/dL at 48 weeks while on background statin therapy 7. The BANTING study (N=421) specifically examined evolocumab in patients with type 2 diabetes and showed a 61.6% LDL-C reduction at 12 weeks on top of statin 14.

For patients who need LDL-C below 70 mg/dL, a high-intensity statin alone may suffice if baseline LDL-C is below 140 mg/dL. For targets below 55 mg/dL from a baseline of 130 mg/dL or higher, adding evolocumab after maximizing statin dose is the standard path recommended by the ACC 11.

Cardiovascular Outcomes Beyond LDL-C

LDL-C is a validated surrogate marker, but hard endpoints matter most. Both drugs have proven cardiovascular event reduction in large randomized trials.

Atorvastatin's evidence base spans primary and secondary prevention. The MIRACL trial (N=3,086) showed that atorvastatin 80 mg started within 24 to 96 hours after acute coronary syndrome reduced recurrent ischemic events by 16% over 16 weeks (P = 0.048) 15. SPARCL (N=4,731) demonstrated a 16% reduction in recurrent stroke with atorvastatin 80 mg in patients with recent stroke or TIA 16. These studies, combined with ASCOT-LLA and TNT, provide four separate lines of outcome evidence for atorvastatin across different vascular territories.

Evolocumab's outcome data comes primarily from FOURIER. A FOURIER substudy examining peripheral artery disease patients (N=3,642) found a 27% reduction in major adverse limb events (HR 0.73, P = 0.0093) 17. Another substudy in patients with prior MI showed a 19% MACE reduction and a 22% reduction in the triple endpoint of CV death, MI, or stroke 18.

One important distinction: FOURIER did not demonstrate a reduction in cardiovascular death (HR 1.05 to 95% CI 0.88 to 1.25) over its 2.2-year follow-up 7. The trial may have been too short to capture mortality differences, given the progressive nature of atherosclerosis.

Safety and Tolerability Differences

Atorvastatin's most common adverse effect is myalgia, reported in 5% to 10% of clinical trial participants. The STOMP trial found that high-intensity statins caused a small but measurable increase in creatine kinase levels, though clinically significant rhabdomyolysis remains rare at approximately 1 in 10,000 patient-years 19. Hepatotoxicity occurs in fewer than 1% of patients. New-onset diabetes risk increases by approximately 9% with statin use, per the CTT meta-analysis, though the cardiovascular benefit substantially outweighs this risk 12.

Evolocumab has a different safety profile. In FOURIER, injection-site reactions occurred in 2.1% of evolocumab patients versus 1.6% with placebo. Neurocognitive events were formally assessed in the EBBINGHAUS substudy (N=1,974), which found no difference between evolocumab and placebo on cognitive function tests over a median of 19 months 20. Nasopharyngitis, upper respiratory tract infection, and back pain occurred at similar rates in both groups 7.

For statin-intolerant patients, evolocumab provides a well-tolerated alternative. GAUSS-3 demonstrated that 95% of patients who could not tolerate two or more statins successfully completed 24 weeks of evolocumab therapy without muscle-related adverse events 10.

Cost and Access Considerations

The cost gap between these two drugs is significant. Generic atorvastatin costs between $4 and $15 per month at most retail pharmacies. The FDA approved generic atorvastatin in 2011, and widespread availability has made it one of the most affordable cardiovascular medications in the world 21.

Evolocumab carries a list price of approximately $5,850 per year. Amgen reduced the list price by 60% in 2018 following cost-effectiveness analyses that questioned the drug's value at the original price point. A 2017 ICER analysis concluded that evolocumab was cost-effective only at an annual price below $2,300 to $3,400 for secondary prevention populations 22. Most commercial insurers and Medicare Part D plans now cover evolocumab with prior authorization, typically requiring documented statin intolerance or LDL-C above 70 mg/dL on maximally tolerated statin therapy.

The FDA approved evolocumab for three indications: heterozygous familial hypercholesterolemia, homozygous familial hypercholesterolemia, and established ASCVD requiring additional LDL-C lowering 23. Atorvastatin carries broader indications including primary prevention in patients with multiple risk factors.

Who Should Get Which Drug

The 2018 AHA/ACC Cholesterol Guideline provides a clear decision pathway. High-intensity statin therapy (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) is the first-line treatment for patients with clinical ASCVD, LDL-C 190 mg/dL or higher, diabetes aged 40 to 75, or elevated 10-year ASCVD risk 9.

PCSK9 inhibitors enter the algorithm at step three. If a patient on maximally tolerated statin plus ezetimibe still has LDL-C at or above 70 mg/dL (for ASCVD patients) or at or above 100 mg/dL (for FH patients without ASCVD), evolocumab or alirocumab becomes the recommended addition 11.

For statin-intolerant patients, the pathway differs. The ACC recognizes evolocumab as an option after a trial of at least two statins and ezetimibe 11. GAUSS-3 supports this approach with evidence that evolocumab lowered LDL-C by 52.8% in patients who could not tolerate statins 10.

Dr. Robert Giugliano, principal investigator of FOURIER, stated in the published trial: "These findings show that inhibiting PCSK9 with evolocumab on a background of statin therapy lowered LDL cholesterol levels to a median of 30 mg per deciliter and significantly reduced the risk of cardiovascular events" 7.

Dr. Peter Sever, lead author of ASCOT-LLA, noted that the trial demonstrated "a significant reduction in cardiovascular events with atorvastatin in hypertensive patients who would not normally be considered for lipid-lowering therapy based on prevailing guidelines" 4.

Patients with very high-risk ASCVD (recurrent events, polyvascular disease, or multiple risk factors) benefit most from the combination. Start atorvastatin 80 mg daily, add ezetimibe 10 mg if LDL-C remains above target after 4 to 6 weeks, then add evolocumab 140 mg subcutaneously every 2 weeks if LDL-C stays at or above 55 mg/dL 13.